APH

Hardman & Co

Alliance Pharma Entering the US market

Alliance Pharma Plc (LON:APH) is continuing with its buy-and-build strategy having evolved through 35 acquisitions over a period of 20 years into a profitable, cash-generative, specialty pharma business. The company

Hardman & Co

Alliance Pharma Kelo-cote building international sales

Alliance Pharma Plc (LON:APH) buy-and-build strategy is to evolve into a profitable, cash generative, specialty pharma business is bearing fruit. Acquisition of the dermatology and wound care products from Sinclair

Hardman & Co

Alliance Pharma Plc Potential of Diclectin

Alliance Pharma plc (LON:APH) buy-and-build strategy which is to evolve into a profitable, cash generative, specialty pharma business is clearly bearing fruit. Acquisition of the dermatology and woundcare products from

Hardman & Co

Alliance Pharma Plc Managing a period of change

Alliance Pharma Plc (LON:APH) has adopted a buy-and-build strategy to evolve through a series of 28 acquisitions into a profitable, cash generative, specialty pharma business. The acquisition of part of